| Company/Division name | Ultragenyx Pharmaceutical |
| Parent company | Ultragenyx Pharmaceutical |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 120 |
| Year reshoring announced: | 2023 |
| Year reshoring implemented or to be implemented: | 2023 |
| City reshored to: | Bedford |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene therapy manufacturing |
| What domestic positive factors made reshoring more attractive? | Better Control of Process/Delivery/Factory, Higher productivity, Manufacturing/engineering joint innovation (R&D) |
